A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
Condition: Carcinoma, Non-Small-Cell Lung Intervention: Sponsor: AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer & Oncology | Carcinoma | Non-Small Cell Lung Cancer | Research | Study